Skip to content

BETTERLIFE PHARMA INC.: 10-Q filed 2012-06-14

What BETTERLIFE PHARMA INC. reported in its quarterly report filed 2012-06-14 (fiscal Q1 2012): 20 published measures, 46 facts as tagged in accession 0001511164-12-000128.

This filing

Form
10-Q (quarterly report)
Filed
2012-06-14
Fiscal period
fiscal Q1 2012
Accession
0001511164-12-000128 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BETTERLIFE PHARMA INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-04-307,144USD
At 2012-01-313,844USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-04-30436,802USD
At 2012-01-311,027,407USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-04-30-429,658USD
At 2012-01-31-1,023,563USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-04-303,486USD
At 2012-01-312,061USD
At 2011-04-3058,538USD
At 2011-01-3115,037USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-02-01 to 2012-04-30593,905USD90
2002-06-10 to 2012-04-30-1,907,892USD3613
2011-02-01 to 2011-04-302,114,892USD89

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-02-01 to 2012-04-30-28,575USD90
2002-06-10 to 2012-04-30-524,680USD3613
2011-02-01 to 2011-04-30-144,369USD89

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-02-01 to 2012-04-3030,000USD90
2002-06-10 to 2012-04-30530,442USD3613
2011-02-01 to 2011-04-30187,870USD89

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2002-06-10 to 2012-04-30-2,276USD3613

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2012-02-01 to 2012-04-3035,767,073shares90
2011-02-01 to 2011-04-3033,621,618shares89

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-04-301,669USD
At 2012-01-311,783USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-04-305,475USD
At 2012-01-312,061USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-02-01 to 2012-04-30-6,529USD90
2002-06-10 to 2012-04-30-68,214USD3613

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-04-30396,677USD
At 2012-01-31866,265USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2002-06-10 to 2012-04-30282,715USD3613
2011-02-01 to 2011-04-3035,208USD89

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-04-30167,086USD
At 2012-01-31167,086USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2012-02-01 to 2012-04-30593,905USD90
2002-06-10 to 2012-04-30-1,907,892USD3613
2011-02-01 to 2011-04-302,114,892USD89

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2012-02-01 to 2012-04-300.02USD90
2011-02-01 to 2011-04-300.06USD89

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-02-01 to 2012-04-302,315USD90
2002-06-10 to 2012-04-30205,476USD3613
2011-02-01 to 2011-04-30105,295USD89

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2012-02-01 to 2012-04-30629,432USD90
2002-06-10 to 2012-04-30-469,045USD3613
2011-02-01 to 2011-04-302,292,471USD89

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2002-06-10 to 2012-04-30307,493USD3613

Inspect the source

Entity
BETTERLIFE PHARMA INC. / CIK 0001464165
Captured
2026-09-20T09:06:34.124Z
SEC response SHA-256
da89258f023cbc29ad1ecdd31014873fa96a7739fba3e7b66a8b80f8715d36cf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001464165.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))